everolimus Archives - Kidney Cancer Support Network

ASCO GU 2021: Combinations of lenvatinib plus pembrolizumab or everolimus improved survival in untreated patients with advanced kidney cancer

Results from the phase 3 CLEAR study, presented at the virtual American Society of Clinical Oncology Genitourinary Cancers Symposium over the weekend, showed that lenvatinib used in combination with either pembrolizumab or everolimus resulted in improved survival and tumour shrinkage compared to sunitinib when used as a first-line treatment for patients with advanced renal cell […]

Feb 15, 2021 / Comments Off / Sharon Kell / Tags: Afinitor, ASCO, combination therapy, everolimus, first-line treatment, Keytruda, lenvatinib, Lenvima, overall survival, pembrolizumab, progression-free survival, renal cell carcinoma

Lenvatinib plus everolimus for non clear cell kidney cancer

Treating non-clear cell renal cell carcinoma (RCC) is challenging because these diseases are rare, and so far there are no effective treatments for this group of patients. Non-clear cell RCC is currently treated in a similar way to clear cell RCC. In a phase 2 clinical trial, 31 patients with non-clear cell RCC were treated […]

Nov 20, 2020 / Comments Off / Sharon Kell / Tags: Afinitor, combination therapy, everolimus, lenvatinib, Lenvima, non-clear cell kidney cancer, renal cell carcinoma

Everolimus and bevacizumab for advanced papillary kidney cancer

In this phase 2 clinical trial, a combination of everolimus plus bevacizumab was looked at in 37 patients with papillary renal cell carcinoma (RCC). The study showed that the combination was effective and delayed progression of the disease (progression-free survival) on average for 13.7 months. There was a response rate of 35%, and overall survival […]

Oct 30, 2020 / Comments Off / Sharon Kell / Tags: Afinitor, Avastin, bevacizumab, everolimus, overall survival, papillary RCC, progression-free survival, renal cell carcinoma, response rate

Phase 1 trial of vorolanib plus everolimus for advanced kidney cancer

A new combination of vorolanib, a tyrosine kinase inhibitor plus everolimus, an mTOR inhibitor shows promise for the treatment of advanced renal cell carcinoma (RCC). A phase 1 study looking at how well the combination is tolerated by patients, safety (side effects), and how the combination works in the body, has shown some promise. Twenty-two […]

May 11, 2020 / Comments Off / Sharon Kell / Tags: Afinitor, everolimus, renal cell carcinoma, vorolanib

ASCO GU 2020: Randomised clinical trial of HIF-2α inhibitor in patients with advanced kidney cancer

A randomised clinical trial of hypoxia inducible factor 2α (HIF-2α) inhibitor, MK-6482, was announced at the American Society of Clinical Oncology (ASCO) Genitourinary (GU) Cancers Symposium in San Francisco last weekend. HIF-2α is known to stimulate the growth of tumours via the von Hippel-Lindau (VLH) group of genes. MK-6482 (also known as PT2977) blocks the […]

Feb 21, 2020 / Comments Off / Sharon Kell / Tags: Afinitor, clinical trials, everolimus, HIF-2α, renal cell carcinoma

ASCO GU 2020: Five-year survival data for metastatic kidney cancer patients treated with nivolumab

Five-year follow-up results from the phase 3 CheckMate-025 study, which compared nivolumab (Opdivo) with everolimus in previously treated advanced or metastatic renal cell carcinoma (RCC), were presented at the American Society of Clinical Oncology (ASCO) Genitourinary (GU) Cancers Symposium in San Francisco last weekend. Nivolumab continues to show superior overall survival and objective response rates […]

Feb 21, 2020 / Comments Off / Sharon Kell / Tags: Afinitor, everolimus, metastases, nivolumab, objective response, Opdivo, overall survival, renal cell carcinoma

Generic everolimus approved by the FDA

The US Food and Drug Administration (FDA) has approved generic everolimus tablets for the treatment of patients with various advanced cancers, including renal cell carcinoma (RCC). Afinitor comes off patent over the next 5 years, after which generic everolimus will become available at a vastly cheaper cost to the NHS. A generic drug is a pharmaceutical drug that contains […]

Dec 11, 2019 / Comments Off / Sharon Kell / Tags: Afinitor, everolimus, FDA, renal cell carcinoma

Panobinostat plus everolimus not effective in metastatic kidney cancer

A recent phase I clinical trial assessed the combination of everolimus (an mTOR inhibitor) with panobinostat (a histone deacetylase inhibitor) in 21 patients with clear-cell metastatic renal cell carcinoma (RCC) who had disease progression within 6 months of stopping treatment with VEGFR TKIs. Median progression-free survival was 4.1 months. Anaemia and thrombocytopenia were the most […]

Nov 14, 2019 / Comments Off / Sharon Kell / Tags: Afinitor, clear cell RCC, everolimus, mTOR inhibitors, panobinostat, progression-free survival, renal cell carcinoma

SMC approves lenvatinib plus everolimus combination for second-line treatment of advanced kidney cancer

We are delighted to announce that the Scottish Medicines Consortium (SMC), which reviews newly licensed medicines in Scotland, has published advice recommending the routine use of lenvatinib plus everolimus for the treatment of patients with advanced renal cell carcinoma (RCC) following one prior VEGF-targeted therapy by NHS Scotland. The lenvatinib plus everolimus combination was accepted following consideration […]

Nov 12, 2019 / Comments Off / Sharon Kell / Tags: Afinitor, everolimus, lenvatinib, Lenvima, renal cell carcinoma, SMC, VEGF inhibitors

ESMO 2019: Results from ENTRATA clinical trial with telaglenastat plus everolimus for pre-treated kidney cancer

Results from the ENTRATA clinical trial to assess telaglenastat in combination with everolimus for patients with heavily pre-treated renal cell carcinoma were presented at the European Society for Medical Oncology (ESMO) conference in Barcelona over the weekend. Telaglenastat is a type of biological therapy called a glutaminase inhibitor that blocks the glutaminase enzyme, which is […]

Sep 30, 2019 / Comments Off / Sharon Kell / Tags: Afinitor, ESMO, everolimus, progression-free survival, renal cell carcinoma, safety and tolerability, telaglenastat

Showing 1 to 10 of 46 results

TOP

Settings

Shopping Bag